0
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Central serous chorioretinopathy secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS)

, , , &
Received 29 Feb 2024, Accepted 27 Jun 2024, Accepted author version posted online: 30 Jul 2024
Accepted author version

REFERENCES

  • Zarnegar A, Ong J, Matsyaraja T, et al. Pathomechanisms in central serous chorioretinopathy: a recent update. Int J Retina Vitreous. 2023;9(1):3. doi: 10.1186/s40942-023-00443-2
  • Van Rijssen, T. J. et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog. Retin. Eye Res. 2019;73:100770. doi: 10.1016/j.preteyeres.2019.07.003
  • Tsai D-C, Chen S-J, Huang C-C, et al. Epidemiology of Idiopathic Central Serous Chorioretinopathy in Taiwan, 2001–2006: A Population-based Study. PLoS One. 2013; 8(6):e66858. doi: 10.1371/journal.pone.0066858. Print 2013
  • Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy. Ophthalmology. 2004;111(2):244–249. doi: 10.1016/j.ophtha.2003.09.024
  • Wong KH, Lau KP, Chhablani J, et al. Central serous chorioretinopathy: what we have learnt so far. Acta Ophthalmol.2016;94(4):321–325. doi: 10.1111/aos.12779. Epub 2015 Jul 1
  • Gawęcki M, Jaszczuk-Maciejewska A, Jurska-Jaśko A, et al. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. BMC Ophthalmol. 2019;19(1):160. doi: 10.1186/s12886-019-1171-5
  • Zhang, X., Lim, Connie Zhi Fong., Chhablani, J., et al.. Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies. Eye and Vis. 2023;10(1):33. doi: 10.1186/s40662-023-00349-y
  • Kouros P. et al. Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment. Klin Monbl Augenheilkd. 2016;233(4),:488–9. doi: 10.1055/s-0041-111805
  • Claiborne RT. et al. Case Report: Erdafitinib-induced Central Serous Chorioretinopathy. Optom Vis Sci. 2022;99(1):88–92. doi: 10.1097/OPX.0000000000001833
  • McConeghy KW, Soriano MM, Danziger LH, et al. A Quantitative Analysis of FDA Adverse Event Reports with Oral Bisphosphonates and Clostridium difficile. Pharmacotherapy. 2016; 36(10):1095–1101. doi: 10.1002/phar.1832. Epub 2016 Sep 25.
  • Van Puijenbroek EP, Van Grootheest K, Diemont WL, et al. Determinants of signal selection in a spontaneous reporting system for adverse drug reactions. Br J Clin Pharmacol. 2001;52(5):579–586. doi: 10.1046/j.0306-5251.2001.01501.x
  • Urban, R. C. et al. Corticosteroid-induced cataracts. Surv Ophthalmol. 1986;31(2):102–110. doi: 10.1016/0039-6257(86)90077-9
  • Garbe, E., LeLorier, J., Boivin, J-F., et al.. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. The Lancet. 1997;350(9083):979–982. doi: 10.1016/S0140-6736(97)03392-8
  • Loriot Y, Necchi A, Park SH, et al. BLC2001 Study Group. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019;381(4):338–348. doi: 10.1056/NEJMoa1817323
  • Haugsten EM, Wiedlocha A, Olsnes S, et al. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res. 2010;8(11):1439–1452. doi: 10.1158/1541-7786.MCR-10-0168
  • Rosenthal R, Malek G, Salomon N, et al. The fibroblast growth factor receptors, FGFR-1 and FGFR-2, mediate two independent signalling pathways in human retinal pigment epithelial cells. Biochem Biophys Res Commun. 2005;337(1):241–247. doi: 10.1016/j.bbrc.2005.09.028
  • Government of Canada. Health Product InfoWatch—November 2019. Balversa™ (erdafitinib). Availableat: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffec t-canada/healthproduct-infowatch/health-product-infowatch-november-2019.html#a3.2. 2021; Accessed October 19
  • Sharma T, Shah N, Rao M, et al. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology. 2004;111(9):1708–1714. doi: 10.1016/j.ophtha.2004.03.025
  • Fan, W. N. et al. Corticosteroids-induced central serous chorioretinopathy: a case of discrimination analysis. Shandong Journal of Traditional Chinese Medicine 2022;41(2): 213–216. 10.16295/j.cnki.0257-358x.2022.02.016
  • Zen, S. M. et al. Glucocorticoid-induced central serous chorioretinopathy after optic nerve schwannoma surgery: a case report. China Journal of Chinese Ophthalmology 2020;30(5):363–364. DOI:10.13444/j.cnki.zgzyykzz.2020.05.015

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.